Shanghai Allist Pharmaceuticals Co., Ltd. (SHA:688578)

Market Cap	40.84B +1.8%
Revenue (ttm)	5.67B +45.0%
Net Income	2.41B +57.4%
EPS	5.36 +57.2%
Shares Out	450.00M
PE Ratio	16.93
Forward PE	15.44
Dividend	1.20 (1.33%)
Ex-Dividend Date	n/a

Volume	3,127,060
Open	90.20
Previous Close	90.37
Day's Range	90.03 - 91.36
52-Week Range	85.41 - 122.20
Beta	0.19
Analysts	Strong Buy
Price Target	128.60 (+41.69%)
Earnings Date	Aug 21, 2026

About SHA:688578

Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of tumor-targeted drugs in China in internationally. The company’s lead product is vometinib mesylate tablet for the treatment of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC). It also develops pralatinib capsules, as well as glerexyl citrate tablets for treating adult patients with locally advanced or metastatic NSCLC. The company was founded in 2004 and is based in Shanghai, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 1,989
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688578

Financial Performance

In 2025, SHA:688578's revenue was 5.19 billion, an increase of 45.80% compared to the previous year's 3.56 billion. Earnings were 2.19 billion, an increase of 53.10%.